The authors have studied the natural history of 377 patients with Stage I cutaneous malignant melanoma followed at the Arizona Cancer Center, Tucson. Two hundred eight patients, or 55%, remained free of metastatic disease after a median follow-up of 30 months. The survival at 5,8, and 10 years was 69, 65, and 63%, respectively. Natural breakpoints in Breslow thickness for survival occurred at 0.85, 1.95, and 4.00 mm. These are not significantly different from those found by other investigators. A step-down multivariate analysis using the Cox regression model yielded four factors as highly significant in predicting survival: Breslow thickness (P < 0.001), an age/sex interaction (P = 0.0012), clinical ulceration (P = 0.0039), and a prophylactic node dissection (P = 0.019). No predictive value for a BANS or non-BANS location was detected. These results are discussed in reference to other large series which describe the natural history of cutaneous melanoma.
I malignant melanoma in order to predict survival and guide the proper Important prognostic factors previously identified have included Breslow 15, 17, 18, 20, 23 From January 1, 1973 to April 1, 1984 , 524 patients with malignant melanoma were followed at the Arizona Cancer Center, Tucson. Clinical history records were compiled from the original diagnosis (histologically proven malignant melanoma) date to the last date of follow-up or death. Staging criteria described by the international union against cancer (IUCC) classification were used.
Of the 524 patients, 440 had Stage I disease at diagnosis. Thirty-eight did not have cutaneous melanoma and were excluded. Twenty-five patients were also excluded as they did not have a wide local excision within 2 months of their diagnosis. We stipulated that the wide excision must be done within 2 months since this is the clinical time frame many patients need to confirm their diagnosis and to seek a second opinion regarding appropriate therapy. Of the 377 evaluable patients with Stage I cutaneous melanoma, 100% had their reports reviewed at our Center, whereas 191 ( 5 1%) had their initial diagnostic slides rereviewed at our center (by B.P.) for the level of involvement according to Clark," depth of penetration in millimeters according to Breslow 
Statistical Analysis
The Kaplan and Meier34 method was used for statistical estimation of the survival-type curves reflecting the time from diagnosis of Stage I disease to the last date of contact or death. Methods used to compare survivaltype curves included the generalized Wilcoxon method of G e h a~~,~~ the log-rank method of and the generalized Kruskal-Wallis method of Bres10w.~~ Multivariate analysis of prognostic factors for survival after Stage I disease used the proportional hazard model introduced by There were only 22 patients with a family history of melanoma, and since there were only three patient deaths, this variable was excluded from the multivariate analysis. Pathologic ulceration also was excluded from the multivariate analysis because of the high number of patients (59%) in which the status of ulceration was unknown.
Results

Survival History of Stage I Melanoma
The survival history of our 377 patients with Stage I cutaneous melanoma who had a surgical wide excision within 2 months of their diagnosis is summarized in Figure 1 . One hundred seventy-five patients (46%) had no evidence of disease after a median time of 32 months from diagnosis. The actuarial survival at 5, 8, and 10 years was 69%, 65%, and 63%, respectively.
Eighty-seven patients of the entire group, or 23%, developed regional nodal metastases (Stage 111, with a median time of 19 months. They were followed for a median time of 28 months after therapeutic lymph node dissection, and 33 (9%) have remained free of disease. The remaining 54 (14%) of the 87 patients developed distant metastases within a median time of 10 months. 
Prognostic Factors Influencing Survival
Eight clinical and four pathologic factors were evaluated retrospectively for their influence on survival in our 377 Stage I patients (Table 1) . Univariate analysis demonstrated that the following features were significantly related to survival duration, with good prognosis: age younger than 50 years, presence of a lesion on an arm or leg (not involving the hand or foot), an age/sex interaction (females < 50 years), absence of clinical ulceration in the primary lesion, a thinner Breslow thickness, a shallower Clark level, a family history of melanoma, female sex, a superficial spreading melanoma, and the absence of pathologic ulceration in the primary lesion. The presence of a non-BANS lesion or a prophylactic lymph node dissection were not statistically beneficial.
A step-down multivariate analysis using the Cox regression model yielded four factors that continued to be prognostic (Table 2 ): a thinner Breslow thickness (vide infra), an age/sex interaction, absence of clinical ulceration, and a prophylactic node dissection. The age/sex interaction showed young women to have the best prognosis, young men and older women to have an intermediate prognosis, and older men to have the worst prognosis. Being female lost its prognostic value once the age and sex interaction was considered.
Natural Breakpoints in Breslow Thickness for Survival
Most authors suggest that one of the most important prognostic factors in predicting regional and distant failure, as well as patient survival, is measurement of the depth of penetration of the cutaneous melanoma into the skin. Of our 377 patients with Stage I disease, 239 
Pi0.001t and below the breakpoint were made until the most accurate and the most significant breakpoint could be determined. The first breakpoint was 0.85 mm. Subsequent analysis was done from 0.85 mm to 10.0 mm, again in 0.1-mm increments until the second breakpoint of 1.95 mm could be determined. The third breakpoint of 4.00 mm was identified in the same manner. A comparison of 5-year survivors of our 377 patients using these natural breakpoints and those described by Balch' and Day et aL4 is shown in Table 3 . There was no significant difference in 5-year survival among comparable subgroups using any of the three schema. The occurrence of Stage I1 and Stage I11 was also compared among the three schema without any significant differences. The generally accepted schema proposed by Balch, therefore, was used in establishing our subgroups for Breslow thickness during multivariate analysis.
Efect of Prophylactic Lymph Node Dissection on Survival
Of the 377 Stage I patients, 100 had a prophylactic lymph node dissection (PLND), 239 did not, and the status was unclear in 38 patients. The group undergoing a PLND had an early survival advantage (P = 0.03, Wilcoxon) and an improved median survival of 84 versus 64 months compared to those patients without a PLND. However, the survival curves crossed and resulted in no significant survival advantage overall (P = 0.37, log-rank).
Discussion
The natural history of cutaneous malignant melanoma in our 377 patients with Stage I disease who underwent a wide local excision within 2 months of their diagnosis compares quite favorably with other authors.'~~ Of our patients, 46% remained free of disease Univariate analysis of 12 prognostic factors revealed ten factors to be favorable and highly significant and one factor to be of marginal significance (Table 1) . Others also have noted these prognostic factors to be significant. 1-32 Multivariate analysis of all 12 prognostic factors revealed four factors to be highly significant and included Breslow thickness, age/sex interaction, absence of clinical ulceration, and a prophylactic lymph node dissection ( Table 2 ).
The Breslow thickness was very significant (P = 0.000 1) on both univariate and multivariate analysis. The Breslow thickness has been found by many authors not only to be highly ~ignificant,',~*~*~-'~~~~-~~ but to be Table 4 , there were no significant differences in the 5-year survival of our 377 patients compared with the 1152 patients reported by Veronesi' and the 155 patients reported by Balch and co-workers.2 The frequency of progression to Stage I1 within 3 years in our patients was slightly lower than those of Balch et af. (Table 5) . However, unlike his study, it is our clinical experience, and that reported by Veronesi,* that there are a small number of patients with 0.75 mm lesions who progress to nodal or distant metastases. The progression to Stage 111 Younger patients ( 4 0 years old) did better (P < 0.00 1 ) on univariate analysis, an observation noted by Women also did better than men on univanate analysis (P = 0.01), a parameter which has been noted by others on univariate3s5v7A11,13-15,17,18,20,23 and multivariate Multivariate analysis of our prognostic factors in patients showed that the age/sex interaction variable replaced age and sex as a prognostic factor. Our study suggests a markedly better prognosis for young women and a poorer prognosis for men and older women on both univariate (P < 0.00 1) and multivariate analysis (P = 0.002). Similar results also have been noted by Davis et all3
Pathologic and clinical ulceration were significant on univariate analysis (P = 0.02 and P < 0.001, respectively) and clinical ulceration remained significant on multivariate analysis (P = 0.0039). Others also have recorded the importance of ulceration, using either univariate9, I 1,13,15, 16 or multivariate analy~es.4.~. 1320, 22729 A family history of melanoma was shown to be highly favorable (P = 0.005) on univariate analysis. Although this was excluded from multivariate analysis because of its uncommon occurrence, many studies support its importance. Before the dysplastic nevus syndrome had been described, patients with multiple primaries had been shown to have a better prognosis independent of the thickness of the lesion. 8 The natural history of the B-K mole syndrome, the dysplastic nevus syndrome, and of patients with multiple primaries currently is under clinical ~t u d y .~' -~~ The site of the primary melanoma was significant on univariate analysis (P < 0.001) but had no significance on multivariate analysis. Primary site has also been shown by others to be significant on univariate and lose its prognostic significance on multivariate analyunivariate analysis was the presence of the superficial spreading variant rather than another primary type (P = 0.01). This fact offered no additional prognostic information after knowing the thickness and location of the primary melanoma, and the age and sex of the patient. The loss of the prognostic significance of the primary type on multivariate analysis has been widely reProphylactic lymph node dissections have been the subject of controversy for years. Some retrospective s t~d i e s~, '~, '~~~~~~~ have shown benefit in certain subgroups, whereas a large prospective study in patients with only extremity lesions has failed to show a benefit. 18 Our study showed that patients undergoing a sis.9,14,16,l8,19,21-23,25,26,36 Also noted to be important on PLND did significantly better initially (Wilcoxon, P = 0.03) but failed to show any benefit as time progressed (log-rank, P = 0.37). However, on multivariate analysis, patients who had had a PLND did markedly better (P = 0.019). Does any subset of patients benefit from a prophylactic lymph node dissection? cant reduction in the incidence of distant metastases (Fig. 3) or a survival advantage in those patients who underwent a PLND (Fig. 4) .
As shown in 0.76 to 1 S O mm group (P = 0.04) and from 37% to 83% in the 1.51 to 3.99 mm group (P = 0.01). The 5-year survival of Balch et a1. ' of 58% in their WLE group of 0.76 to 1.50 mm is very low (82% in our patients, and from 70%-82% as reported by Breslow,' Kapelan~ki,'~ and Veronesi'). For the 1.5 1 to 3.99 mm subgroup, our overall 5-year survival of 73% and the overall 5-year survival of Balch et a1.' of 68% are quite close to the 65% survival reported by Veronesi.' However, there may be some type of patient selection differences between our two groups since our patients with WLE alone (N = 54) did significantly better (72% 5-year survival) compared to the WLE alone group (N = 18) of Balch et aL2 with a 37% 5-year survival.
Veronesi et a1.,28 in a large clinical trial, reported that there was no statistical survival benefit in a prospective trial of WLE versus WLE + PLND in patients with lesions on the extremity. Critics of this trial point to the large proportion of women in the study who may have had a better prognosis, the trend (P = 0.13) of better survival in those patients with 3.0 to 3.9 mm thick lesions undergoing WLE + PLND, and the difficulty of detecting statistical significance since extremity lesions have the best prognosis. It is clear that the effect of a PLND for subgroups of patients with different Breslow thicknesses requires further investigation.
The results reported by Day et a1." for BANS and non-BANS lesions and our results differ in several areas (Table 7) . Their 8-year survival of 99% for all patients with lesions -= 0.85 mm is high compared with the 87% 8-year survival of our patients and the 89% reported by Veronesi.' Their 99% 8-year survival in patients with non-BANS lesions 0.85 to 1.69 mm thick is high when compared to our 82% survival. The 93% 8-year survival for all patients with lesions 0.85 to 1.69 mm thick also is high when compared to our 82% survival, the 82% survival reported by Veronesi,' the 70% 5-year survival reported by Breslow,' and the 64% 5-year survival reported by Balch Therefore, our data support the usage of those subgroups described by Balch et a1. ' and Breslow as a standard reference. Multivariate analysis revealed four highly significant prognostic variables for predicting survival: thinner Breslow thickness, an age/sex interaction, absence of clinical ulceration, and a prophylactic lymph node dissection. The use of this information will continue to help us in the assessment of the natural history of cutaneous melanoma and biological features underlying the clinical variability of the disease.40
